TTD | Drug: D06PZC

Drug General Information
Drug ID	D06PZC
Former ID	DIB011107
Drug Name	SAM-6
Drug Type	Antibody
Indication	Melanoma [ICD9: 172; ICD10:C43]		Phase 1	[524124]
Company	Pack of Parker; OncoMab GmbH
Target and Pathway
Target(s)	78 kDa glucose-regulated protein	Target Info		[529312]
KEGG Pathway	Protein export
	Protein processing in endoplasmic reticulum
	Antigen processing and presentation
	Thyroid hormone synthesis
	Prion diseases
NetPath Pathway	TSH Signaling Pathway
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Apoptosis signaling pathway
PANTHER Pathway	Parkinson disease
PathWhiz Pathway	Retinol Metabolism
Reactome	Platelet degranulation
Reactome	Regulation of HSF1-mediated heat shock response
WikiPathways	MAPK Signaling Pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Activation of Chaperone Genes by ATF6-alpha
	Parkin-Ubiquitin Proteasomal System pathway
	Unfolded Protein Response
	Response to elevated platelet cytosolic Ca2+
References
Ref 524124	ClinicalTrials.gov (NCT01727778) Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 529312	A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information